Literature DB >> 9740699

The role of adjuvant radiotherapy in carcinoma of the endometrium-results in 550 patients with pathologic stage I disease.

C Irwin1, W Levin, A Fyles, M Pintilie, L Manchul, P Kirkbride.   

Abstract

OBJECTIVES: A retrospective analysis of 550 women with pathological stage I carcinoma of the endometrium who were seen between January 1984 and December 1988 was performed in order to assess the value of adjuvant radiation therapy.
METHODS: Two-hundred twenty-eight patients were treated with surgery alone (S); 97 received adjuvant external beam radiotherapy (S + EXT); 217 received external beam radiotherapy and colpostats (S + EXT + IC); and 8 patients received only colpostats (S + IC). Pelvic radiation therapy, usually 40 Gy in 20 fractions, was administered to 94% of patients whose tumors showed greater than 50% myometrial invasion and to 89% of patients with FIGO grade 3 tumors. Colpostats were used in 40% of patients, the majority of whom had lower uterine segment involvement.
RESULTS: The overall survival rate for the whole group using Kaplan-Meier estimates was 84% at 5 years. The 5-year overall survival rates for each treatment group, excluding the S + IC group, were 90% for S alone, 79% for S + EXT, and 82% for S + EXT + IC. The 5-year disease-free survival rates were 84, 77, and 77%, respectively. Local control rates at 5 years were 93, 94, and 95% in the three treatment groups, but the patterns of relapse were different. Distant metastases occurred more frequently among the patients who received adjuvant radiation therapy (36/49, 73%) than among those who did not (4/19, 21%). Late toxicity was documented in 66 patients. Twelve patients had EORTC/RTOG grade 3 and 4 complications; all had been treated with S + EXT + IC. FIGO grade (P = 0.009), lower uterine segment involvement (P = 0.009), and age (P = 0.03) were significant predictors of worse disease-free survival in a multiple regression analysis.
CONCLUSIONS: The addition of vaginal vault brachytherapy to external beam radiotherapy did not appear to improve local cure rates nor survival, but increased the incidence of late radiation toxicity. Copyright 1998 Academic Press.

Entities:  

Mesh:

Year:  1998        PMID: 9740699     DOI: 10.1006/gyno.1998.5064

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  10 in total

1.  The effect of lymphadenectomy and radiotherapy on recurrence and survival in endometrial carcinoma. Experience in a population reference centre.

Authors:  Meritxell Arenas; Marina Gascón; Àngels Rovirosa; Víctor Hernández; Francesc Riu; Iolanda López; Angel Montero; Sebastià Sabater
Journal:  Rep Pract Oncol Radiother       Date:  2014-10-14

Review 2.  Systemic therapy for advanced or recurrent endometrial carcinoma.

Authors:  G F Fleming
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

Review 3.  Long-term urinary adverse effects of pelvic radiotherapy.

Authors:  Sean P Elliott; Bahaa S Malaeb
Journal:  World J Urol       Date:  2010-10-20       Impact factor: 4.226

4.  The effect of postoperative beam, implant, and combination radiation therapy on GI and bladder toxicities in female Medicare beneficiaries with stage I uterine cancer.

Authors:  Rafael Samper-Ternent; Humera Asem; Dong D Zhang; Yong-Fang Kuo; Sandra S Hatch; Jean L Freeman; Abbey B Berenson
Journal:  J Geriatr Oncol       Date:  2012-07-18       Impact factor: 3.599

5.  High-risk surgical stage 1 endometrial cancer: analysis of treatment outcome.

Authors:  Gustavo A Viani; Barbara F Patia; Antonio C Pellizzon; Marcel D De Melo; Paulo E Novaes; Ricardo C Fogaroli; Maria A Conte; Joao V Salvajoli
Journal:  Radiat Oncol       Date:  2006-08-03       Impact factor: 3.481

6.  Postoperative Radiotherapy Alone Versus Chemoradiotherapy in Stage I-II Endometrial Carcinoma: An Investigational and Propensity Score Matching Analysis.

Authors:  Jong Hoon Lee; Hyo Chun Lee; Sung Hwan Kim; Mi Joo Chung; Song Mi Jeong; Sung Jong Lee; Joo Hee Yoon; Dong Choon Park
Journal:  Cancer Res Treat       Date:  2014-09-15       Impact factor: 4.679

7.  Should the Optimal Adjuvant Treatment for Patients With Early-Stage Endometrial Cancer With High-Intermediate Risk Factors Depend on Tumor Grade?

Authors:  Chunyan Lan; Xin Huang; Qidan Huang; Yin Wang; Haifeng Gu; Yong Li; Jihong Liu
Journal:  Int J Gynecol Cancer       Date:  2015-10       Impact factor: 3.437

8.  Preponderance of endometrial carcinoma in elderly patients.

Authors:  Naoki Ogane; Shin-Ichi Hori; Mitsutake Yano; Tomomi Katoh; Shingo Kamoshida; Hisamori Kato; Yoichi Kameda; Masanori Yasuda
Journal:  Mol Clin Oncol       Date:  2018-07-19

9.  Risk factors for recurrence amongst high intermediate risk patients with endometrioid adenocarcinoma.

Authors:  Agnes Y Bahng; Christina Chu; Paul Wileyto; Stephen Rubin; Lilie L Lin
Journal:  J Gynecol Oncol       Date:  2012-09-19       Impact factor: 4.401

10.  Postoperative radiotherapy for endometrial cancer.

Authors:  Eun Cheol Choi; Jin Hee Kim; Ok Bae Kim; Sang Jun Byun; Seung Gyu Park; Sang Hoon Kwon
Journal:  Radiat Oncol J       Date:  2012-09-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.